Overview
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
Status:
Recruiting
Recruiting
Trial end date:
2023-12-01
2023-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether a medication, Clonidine can reduce the number of days a baby spends in the hospital and the number of days of medical treatment of withdrawal from Neonatal Abstinence Syndrome (NAS) as compared to Morphine Sulfate (used in routine care) .Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
The Cooper Health SystemTreatments:
Clonidine
Morphine
Criteria
Inclusion Criteria:- Born at Cooper University Hospital
- Greater than or equal to 35 weeks gestation age
- Admitted to the NICU or Transitional nursery
- Mothers admitted to using illicit substances or prescription medications (which can
result in withdrawal symptoms) while pregnant and/or had a positive urine drug screen
during pregnancy.
- Babies being started on medication to control withdrawal symptoms of NAS.
- No congenital anomalies or neurologic condition (i.e. hypoxic-ischemic encephalopathy,
seizures, meningitis etc.)
Exclusion Criteria:
- Premature infants <35 week gestational age
- Infants with major congenital abnormalities
- Blood pressure instability
- Major medical conditions